Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

Thomas G. Beach, Charles L. White, Christa L. Hladik, Marwan N. Sabbagh, Donald J. Connor, Holly A. Shill, Lucia I. Sue, Jeanne Sasse, Jyothi Bachalakuri, Jonette Henry-Watson, Haru Akiyama, Charles H. Adler

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Involvement of the olfactory bulb by Lewy-type α-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical α-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included α-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalActa Neuropathologica
Volume117
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Lewy Bodies
Olfactory Bulb
Lewy Body Disease
Sensitivity and Specificity
Parkinson Disease
Alzheimer Disease
Synucleins
Brain
Staining and Labeling
Brain Stem
Dementia
Biopsy

Keywords

  • α-Synuclein, Lewy bodies, incidental Lewy body disease
  • Biopsy
  • Deep brain stimulation
  • Dementia with Lewy bodies, diagnosis, therapy, clinical trial
  • Gene therapy
  • Olfactory bulb
  • Parkinson's disease, surgery
  • Transplantation

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Beach, T. G., White, C. L., Hladik, C. L., Sabbagh, M. N., Connor, D. J., Shill, H. A., ... Adler, C. H. (2009). Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathologica, 117(2), 169-174. https://doi.org/10.1007/s00401-008-0450-7

Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. / Beach, Thomas G.; White, Charles L.; Hladik, Christa L.; Sabbagh, Marwan N.; Connor, Donald J.; Shill, Holly A.; Sue, Lucia I.; Sasse, Jeanne; Bachalakuri, Jyothi; Henry-Watson, Jonette; Akiyama, Haru; Adler, Charles H.

In: Acta Neuropathologica, Vol. 117, No. 2, 2009, p. 169-174.

Research output: Contribution to journalArticle

Beach, TG, White, CL, Hladik, CL, Sabbagh, MN, Connor, DJ, Shill, HA, Sue, LI, Sasse, J, Bachalakuri, J, Henry-Watson, J, Akiyama, H & Adler, CH 2009, 'Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders', Acta Neuropathologica, vol. 117, no. 2, pp. 169-174. https://doi.org/10.1007/s00401-008-0450-7
Beach, Thomas G. ; White, Charles L. ; Hladik, Christa L. ; Sabbagh, Marwan N. ; Connor, Donald J. ; Shill, Holly A. ; Sue, Lucia I. ; Sasse, Jeanne ; Bachalakuri, Jyothi ; Henry-Watson, Jonette ; Akiyama, Haru ; Adler, Charles H. / Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. In: Acta Neuropathologica. 2009 ; Vol. 117, No. 2. pp. 169-174.
@article{8848b0db869b442cbe83ea7293210b07,
title = "Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders",
abstract = "Involvement of the olfactory bulb by Lewy-type α-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical α-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included α-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91{\%} for PD versus elderly control; 97 and 91{\%} for DLB versus elderly control; 88 and 91{\%} for ADLS versus elderly control; 88 and 81{\%} for ADLS versus ADNLS; 67 and 91{\%} for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.",
keywords = "α-Synuclein, Lewy bodies, incidental Lewy body disease, Biopsy, Deep brain stimulation, Dementia with Lewy bodies, diagnosis, therapy, clinical trial, Gene therapy, Olfactory bulb, Parkinson's disease, surgery, Transplantation",
author = "Beach, {Thomas G.} and White, {Charles L.} and Hladik, {Christa L.} and Sabbagh, {Marwan N.} and Connor, {Donald J.} and Shill, {Holly A.} and Sue, {Lucia I.} and Jeanne Sasse and Jyothi Bachalakuri and Jonette Henry-Watson and Haru Akiyama and Adler, {Charles H.}",
year = "2009",
doi = "10.1007/s00401-008-0450-7",
language = "English (US)",
volume = "117",
pages = "169--174",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

AU - Beach, Thomas G.

AU - White, Charles L.

AU - Hladik, Christa L.

AU - Sabbagh, Marwan N.

AU - Connor, Donald J.

AU - Shill, Holly A.

AU - Sue, Lucia I.

AU - Sasse, Jeanne

AU - Bachalakuri, Jyothi

AU - Henry-Watson, Jonette

AU - Akiyama, Haru

AU - Adler, Charles H.

PY - 2009

Y1 - 2009

N2 - Involvement of the olfactory bulb by Lewy-type α-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical α-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included α-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

AB - Involvement of the olfactory bulb by Lewy-type α-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical α-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included α-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

KW - α-Synuclein, Lewy bodies, incidental Lewy body disease

KW - Biopsy

KW - Deep brain stimulation

KW - Dementia with Lewy bodies, diagnosis, therapy, clinical trial

KW - Gene therapy

KW - Olfactory bulb

KW - Parkinson's disease, surgery

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=59249083870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249083870&partnerID=8YFLogxK

U2 - 10.1007/s00401-008-0450-7

DO - 10.1007/s00401-008-0450-7

M3 - Article

VL - 117

SP - 169

EP - 174

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 2

ER -